ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026

Impact · against what's priced in

The announcement of a future presentation of quality of life data is a low-impact event, as the primary clinical efficacy (PFS) has already been established. While it supports the overall profile of 177 Lu-edotreotide, the market will remain focused on the pending FDA review for regulatory approval.

ITM+0.10

No priced-in read yet